X4 Pharmaceuticals Presents New Clinical and Scientific Data at 2021 ASH Annual Meeting Supporting Broader Potential for Mavorixafor in the Treatment of Primary Immunodeficiencies
December 13, 2021 08:00 ET
|
X4 Pharmaceuticals
- Presented data highlight mavorixafor’s ability to raise the spectrum of white blood cell counts across a broad range of diseases with or without CXCR4 mutations including Chronic Neutropenia - -...
X4 Pharmaceuticals Presents New Clinical Data at ASH 2021 Further Supporting Potential of Mavorixafor + Ibrutinib to Treat Patients with Double-Mutation Waldenström’s Macroglobulinemia
December 11, 2021 09:00 ET
|
X4 Pharmaceuticals
- CXCR4 antagonism proof of concept established, with 100% overall response rate to combination treatment in frontline and refractory patients - - Median Serum IgM reductions in refractory CXCR4MUT...
X4 Pharmaceuticals to Host Virtual Seminar “Understanding Primary Immunodeficiencies” to Highlight Broadening Market Opportunities for Mavorixafor
December 02, 2021 06:05 ET
|
X4 Pharmaceuticals
Company to present new clinical data supporting the expanded potential use of mavorixafor to treat a broad array of immunodeficiencies as well as new insights into WHIM syndrome Guest speakers...
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 01, 2021 16:05 ET
|
X4 Pharmaceuticals
BOSTON, Dec. 01, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients...
X4 Pharmaceuticals to Participate in Stifel’s Virtual Healthcare Conference
November 10, 2021 08:00 ET
|
X4 Pharmaceuticals
BOSTON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people...
X4 Pharmaceuticals to Have Strong Presence at ASH 2021 with Seven Accepted Abstracts Highlighting New Clinical and Scientific Data; Company Reports Third Quarter Financial Results
November 04, 2021 09:01 ET
|
X4 Pharmaceuticals
Data continue to support mavorixafor’s potential to benefit patients with WHIM syndrome, chronic neutropenia, and Waldenström’s macroglobulinemia Discovery of new prevalent WHIM variant further...
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 01, 2021 16:05 ET
|
X4 Pharmaceuticals
BOSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients...
X4 Pharmaceuticals to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 4, 2021
October 25, 2021 08:00 ET
|
X4 Pharmaceuticals
BOSTON, Oct. 25, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients...
X4 Pharmaceuticals Expands Commercial Leadership Expertise with Appointment of Françoise de Craecker to Board of Directors and Karolyn Park as Vice President, U.S. Commercial
October 19, 2021 08:00 ET
|
X4 Pharmaceuticals
BOSTON, Oct. 19, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients...
X4 Pharmaceuticals Completes Enrollment in Phase 3 Mavorixafor Trial in Patients with WHIM Syndrome
October 04, 2021 08:00 ET
|
X4 Pharmaceuticals
Final enrollment of 31 adult and pediatric patients exceeds initial target of 18-28 patients Top-line data expected in 4Q 2022; U.S. NDA filing anticipated in 1Q 2023 BOSTON, Oct. 04, 2021 (GLOBE...